| Ticker Symbol: | CGRB |
|---|---|
| Exchange: | NASD |
| Contact Info: | 10990 Wilshire Boulevard Los Angeles CA 90024 310-943-8040 |
| CEO/President: | |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar Biotechnology is a publicly held biotechnology company established to in-license and develop early clinical stage drugs, with a specific focus on the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. |
| Shares Outstanding: | 20,570 (000) | Market Value: | 360,950 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 69.96% | Number of Inst.Shareholders: | 9.90% |
| Last Quarter Sales: | 0.00 ($Mil.) | Last Quarter Net Income: | -15.58 ($Mil.) |
| Last Quarter EPS: | -0.76 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -1.50 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| AMGEN | +12.60 | 58.23 | |
| GILEAD SCIENCES | -1.00 | 46.92 | |
| CELGENE CP | -10.00 | 58.86 | |
| BIOGEN IDEC INC | -31.90 | 43.52 | |
| AMYLIN PHARMA I | -85.70 | 6.41 |
